By Professor Andrew Lloyd

Journal articles

Murphy CE; Walker AK; O’Donnell M; Galletly C; Lloyd AR; Liu D; Weickert CS; Weickert TW; ODonnell M, 2022, 'Peripheral NF-κB dysregulation in people with schizophrenia drives inflammation: putative anti-inflammatory functions of NF-κB kinases', Translational Psychiatry, 12, pp. 21, http://dx.doi.org/10.1038/s41398-021-01764-2

Carson JM; Dore GJ; Lloyd AR; Grebely J; Byrne M; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Matthews GV; Hajarizadeh B, 2022, 'Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study', Clinical Infectious Diseases, 75, pp. 1809 - 1819, http://dx.doi.org/10.1093/cid/ciac246

Adhikari A; Abayasingam A; Rodrigo C; Agapiou D; Pandzic E; Brasher NA; Fernando BSM; Keoshkerian E; Li H; Kim HN; Lord M; Popovic G; Rawlinson W; Mina M; Post JJ; Hudson B; Gilroy N; Dwyer D; Sasson SC; Grubor-Bauk B; Lloyd AR; Martinello M; Bull RA; Tedla N; Lloyd AR; Kaldor J; Dore G; Sorrell T; Hudson B; Bartlett A; Lemberg D; Di Girolamo N; Byrne M; Hammoud M; Lloyd AR; Sultan R; Hudson B; Konecny P; Matthews G; Shek D; Holdaway S; Mitsa-Kos K; How-Chow D; Lagunday R; Robinson S; Terrill L; Joshi N; Li Y; Gill S; Sevehon A, 2022, 'Longitudinal Characterization of Phagocytic and Neutralization Functions of Anti-Spike Antibodies in Plasma of Patients after Severe Acute Respiratory Syndrome Coronavirus 2 Infection', Journal of Immunology, 209, pp. 1499 - 1512, http://dx.doi.org/10.4049/jimmunol.2200272

Lafferty L; Rance J; Byrne M; Milat A; Dore GJ; Grebely J; Lloyd AR; Treloar C, 2022, '“You need a designated officer” – Recommendations from correctional and justice health personnel for scaling up hepatitis C treatment-as-prevention in the prison setting', International Journal of Drug Policy, 106, http://dx.doi.org/10.1016/j.drugpo.2022.103746

Sandler CX; Cvejic E; Valencia BM; Li H; Hickie IB; Lloyd AR, 2022, 'Predictors of Chronic Fatigue Syndrome and Mood Disturbance After Acute Infection', Frontiers in Neurology, 13, http://dx.doi.org/10.3389/fneur.2022.935442

Akiyama MJ; Kronfli N; Cabezas J; Sheehan Y; Scheibe A; Brahni T; Naik K; Mashabela P; Chan P; Luhmann N; Lloyd AR, 2022, 'The role of low-income and middle-income country prisons in eliminating hepatitis C', The Lancet Public Health, 7, pp. e578 - e579, http://dx.doi.org/10.1016/S2468-2667(22)00119-0

Howe AYM; Rodrigo C; Cunningham EB; Douglas MW; Dietz J; Grebely J; Popping S; Sfalcin JA; Parczewski M; Sarrazin C; de Salazar A; Fuentes A; Sayan M; Quer J; Kjellin M; Kileng H; Mor O; Lennerstrand J; Fourati S; Di Maio VC; Chulanov V; Pawlotsky JM; Harrigan PR; Ceccherini-Silberstein F; Garcia F; Martinello M; Matthews G; Fernando FF; Esteban JI; Müllhaupt B; Wiesch JSZ; Buggisch P; Neumann-Haefelin C; Berg T; Berg CP; Schattenberg JM; Moreno C; Stauber R; Lloyd A; Dore G; Applegate T; Ignacio J; Garcia-Cehic D; Gregori J; Rodriguez-Frias F; Rando A; Gozlan Y; Angelico M; Andreoni M; Babudieri S; Bertoli A; Cento V; Coppola N; Craxì A; Paolucci S; Parruti G; Pasquazzi C; Perno CF; Teti E; Vironet C; Lannergård A; Duberg AS; Aleman S; Gutteberg T; Soulier A; Gourgeon A; Chevaliez S; Pol S; Carrat F; Salmon D; Kaiser R; Knopes E; Gomes P; de Kneght R; Rijnders B; Poljak M; Lunar M; Usubillaga R; Seguin_Devaux C; Tay E; Wilson C; Wang DS; George J; Kok J; Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A, 2022, 'Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals', JHEP Reports, 4, pp. 100462, http://dx.doi.org/10.1016/j.jhepr.2022.100462

Riaz N; Leung P; Bull RA; Lloyd AR; Rodrigo C, 2022, 'Evolution of within-host variants of the hepatitis C virus', Infection, Genetics and Evolution, 99, pp. 105242, http://dx.doi.org/10.1016/j.meegid.2022.105242

Verveen A; Müller F; Lloyd A; Moss-Morris R; Omland T; Penninx B; Raijmakers RPH; van der Schaaf M; Sandler CX; Stavem K; Wessely S; Wyller VBB; Nieuwkerk P; Knoop H, 2022, 'A research agenda for post-COVID-19 fatigue', Journal of Psychosomatic Research, 154, http://dx.doi.org/10.1016/j.jpsychores.2022.110726

Balachandran H; Phetsouphanh C; Agapiou D; Adhikari A; Rodrigo C; Hammoud M; Shrestha LB; Keoshkerian E; Gupta M; Turville S; Christ D; King C; Sasson SC; Bartlett A; Grubor-Bauk B; Rawlinson W; Aggarwal A; Stella AO; Klemm V; Mina MM; Post JJ; Hudson B; Gilroy N; Konecny P; Ahlenstiel G; Dwyer DE; Sorrell TC; Kelleher A; Tedla N; Lloyd AR; Martinello M; Bull RA, 2022, 'Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses', Cell Reports, 38, pp. 110345, http://dx.doi.org/10.1016/j.celrep.2022.110345

Mostafavi H; Tharmarajah K; Vider J; West NP; Freitas JR; Cameron B; Foster PS; Hueston LP; Lloyd AR; Mahalingam S; Zaid A, 2022, 'Interleukin-17 contributes to Ross River virus-induced arthritis and myositis', PLoS Pathogens, 18, http://dx.doi.org/10.1371/journal.ppat.1010185

Lafferty L; Cochrane A; Sheehan Y; Treloar C; Grebely J; Lloyd AR, 2022, '“That was quick, simple, and easy”: Patient perceptions of acceptability of point-of-care hepatitis C RNA testing at a reception prison', International Journal of Drug Policy, 99, http://dx.doi.org/10.1016/j.drugpo.2021.103456

Casson S; Jones MD; Cassar J; Kwai N; Lloyd AR; Barry BK; Sandler CX, 2022, 'The effectiveness of activity pacing interventions for people with chronic fatigue syndrome: a systematic review and meta-analysis', Disability and Rehabilitation, 45, pp. 3788 - 3802, http://dx.doi.org/10.1080/09638288.2022.2135776

Riaz N; Leung P; Barton K; Smith MA; Carswell S; Bull R; Lloyd AR; Rodrigo C, 2021, 'Adaptation of Oxford Nanopore technology for hepatitis C whole genome sequencing and identification of within-host viral variants', BMC Genomics, 22, pp. 148, http://dx.doi.org/10.1186/s12864-021-07460-1

Rance J; Lafferty L; Treloar C; Loveday S; Dore G; Lloyd A; Grebely J; Butler T; Martin N; Chambers G; Byrne M; Donnelly R; McGrath C; Bowman J; Trevethan L; Grant L; Murrell T; Bath N; Harrod M; Churchill A; Pinnock K; Cairnduff S, 2021, 'Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian ‘surveillance and treatment of prisoners with hepatitis C’ project (SToP-C)', Harm Reduction Journal, 18, pp. 46, http://dx.doi.org/10.1186/s12954-021-00494-4

Lafferty L; Rance J; Dore GJ; Grebely J; Lloyd AR; Treloar C, 2021, 'Hepatitis C treatment as prevention in the prison setting: Assessments of acceptability of treatment scale up efforts by prison correctional and health personnel', International Journal of Drug Policy, 98, http://dx.doi.org/10.1016/j.drugpo.2021.103379

Lim AG; Stone J; Hajarizadeh B; Byrne M; Chambers GM; Martin NK; Grebely J; Dore GJ; Lloyd AR; Vickerman P, 2021, 'Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP-C Treatment as Prevention Study in Prisons', Hepatology, 74, pp. 2366 - 2379, http://dx.doi.org/10.1002/hep.32002

Rance J; Lafferty L; Treloar C; Loveday S; Dore G; Lloyd A; Grebely J; Butler T; Martin N; Chambers G; Byrne M; Donnelly R; McGrath C; Bowman J; Trevethan L; Grant L; Murrell T; Bath N; Harrod M; Churchill A; Pinnock K; Cairnduff S, 2021, 'Expert stakeholder perspectives on the acceptability of treatment-as-prevention in prison: a qualitative substudy of the ‘Surveillance and Treatment of Prisoners with Hepatitis C’ project (SToP-C)', Addiction, 116, pp. 2761 - 2769, http://dx.doi.org/10.1111/add.15477

Sandler CX; Wyller VBB; Moss-Morris R; Buchwald D; Crawley E; Hautvast J; Katz BZ; Knoop H; Little P; Taylor R; Wensaas KA; Lloyd AR, 2021, 'Long COVID and post-infective fatigue syndrome: A review', Open Forum Infectious Diseases, 8, http://dx.doi.org/10.1093/ofid/ofab440

Li H; Cvejic E; Gu B; Vollmer-Conna U; Hickie I; Wakefield D; Davenport T; Wiley J; Lloyd AR, 2021, 'Regulation of the Acute Sickness Response by the P2RX7 Receptor', Journal of Infectious Diseases, 224, pp. 914 - 920, http://dx.doi.org/10.1093/infdis/jiab027

Li SH; Lloyd AR; Graham BM, 2021, 'Subjective sleep quality and characteristics across the menstrual cycle in women with and without Generalized Anxiety Disorder', Journal of Psychosomatic Research, 148, http://dx.doi.org/10.1016/j.jpsychores.2021.110570

Adhikari A; Eltahla A; Lloyd AR; Rodrigo C; Agapiou D; Bull RA; Tedla N, 2021, 'Optimisation and validation of a new method for antibody dependent cellular phagocytosis in hepatitis C virus infection', Journal of Immunological Methods, 495, http://dx.doi.org/10.1016/j.jim.2021.113087

Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ; Loveday S; Tamaddoni M; Obeid S; Estivill Mercade G; Martinez M; Donnelly R; Bowman J; Trevethan L; Lagios K; Murrell T; Bath N; Tawil V; Stevens A; Topp L; Churchill A; Pinnock K; Martin N; Drew S; Harrod M; Smith A; Williams R; Cooper B; Somes K; Burns C; Kaur A; Lobo C; Conroy K; McCredie L; Café C; Anlezark J; Rawlinson W; Yeang M; Wynn M; Willenborg C, 2021, 'Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study', The Lancet Gastroenterology and Hepatology, 6, pp. 533 - 546, http://dx.doi.org/10.1016/S2468-1253(21)00077-7

Zhao Y; Cai C; Samir J; Palgen JL; Keoshkerian E; Li H; Bull RA; Luciani F; An H; Lloyd AR, 2021, 'Human CD8 T-stem cell memory subsets phenotypic and functional characterization are defined by expression of CD122 or CXCR3', European Journal of Immunology, 51, pp. 1732 - 1747, http://dx.doi.org/10.1002/eji.202049057

Brasher NA; Adhikari A; Lloyd AR; Tedla N; Bull RA, 2021, 'Hepatitis c virus epitope immunodominance and b cell repertoire diversity', Viruses, 13, pp. 983, http://dx.doi.org/10.3390/v13060983

Akiyama MJ; Kronfli N; Cabezas J; Sheehan Y; Thurairajah PH; Lines R; Lloyd AR, 2021, 'Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework', The Lancet Gastroenterology and Hepatology, 6, pp. 391 - 400, http://dx.doi.org/10.1016/S2468-1253(20)30365-4

Lafferty L; Rance J; Dore GJ; Lloyd AR; Treloar C, 2021, 'The role of social capital in facilitating hepatitis C treatment scale-up within a treatment-as-prevention trial in the male prison setting', Addiction, 116, pp. 1162 - 1171, http://dx.doi.org/10.1111/add.15277

Abayasingam A; Balachandran H; Agapiou D; Hammoud M; Rodrigo C; Keoshkerian E; Li H; Brasher NA; Christ D; Rouet R; Burnet D; Grubor-Bauk B; Rawlinson W; Turville S; Aggarwal A; Stella AO; Fichter C; Brilot F; Mina M; Post JJ; Hudson B; Gilroy N; Dwyer D; Sasson SC; Tea F; Pilli D; Kelleher A; Tedla N; Lloyd AR; Martinello M; Bull RA; Burnett D, 2021, 'Long-term persistence of RBD⁺ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection', Cell Reports Medicine, 2, pp. 100228, http://dx.doi.org/10.1016/j.xcrm.2021.100228

Valencia BM; Cvejic E; Vollmer-Conna U; Hickie IB; Wakefield D; Li H; Pedergnana V; Rodrigo C; Lloyd AR; Valencia Arroyo BM, 2021, 'The severity of the pathogen-induced acute sickness response is affected by polymorphisms in genes of the NLRP3 inflammasome pathway', Brain, Behavior, and Immunity, 93, pp. 186 - 193, http://dx.doi.org/10.1016/j.bbi.2021.01.005

Kwon JA; Chambers GM; Luciani F; Zhang L; Kinathil S; Kim D; Thein HH; Botha W; Thompson S; Lloyd A; Yap L; Gray RT; Butler T, 2021, 'Hepatitis C treatment strategies in prisons: A cost-effectiveness analysis', PLoS ONE, 16, pp. e0245896, http://dx.doi.org/10.1371/journal.pone.0245896

Seddiki N; Zaunders J; Phetsouphanh C; Brezar V; Xu Y; McGuire HM; Bailey M; McBride K; Hey-Cunningham W; Munier CML; Cook L; Kent S; Lloyd A; Cameron B; De St Groth BF; Koelsch K; Danta M; Hocini H; Levy Y; Kelleher AD, 2021, 'CD73⁺ CD127^high long-term memory CD4 T cells are highly proliferative in response to recall antigens and are early targets in hiv-1 infection', International Journal of Molecular Sciences, 22, pp. 1 - 28, http://dx.doi.org/10.3390/ijms22020912

Cameron B; Webber K; Li H; Bennett BK; Boyle F; de Souza P; Wilcken N; Lynch J; Friedlander M; Goldstein D; Lloyd AR, 2021, 'Genetic associations of fatigue and other symptoms following breast cancer treatment: A prospective study', Brain, Behavior, and Immunity - Health, 10, pp. 100189, http://dx.doi.org/10.1016/j.bbih.2020.100189

Miller K; Treloar C; Lloyd AR, 2021, 'People in prison who inject drugs: who is trusted when it comes to information about hepatitis C?', Addiction Research and Theory, 29, pp. 247 - 254, http://dx.doi.org/10.1080/16066359.2021.1879058

Adikari TN; Riaz N; Sigera C; Leung P; Valencia BM; Barton K; Smith MA; Bull RA; Li H; Luciani F; Weeratunga P; Thein TL; Lim VWX; Leo YS; Rajapakse S; Fink K; Lloyd AR; Fernando D; Rodrigo C; Valencia Arroyo BM, 2020, 'Single molecule, near full-length genome sequencing of dengue virus', Scientific Reports, 10, pp. 18196, http://dx.doi.org/10.1038/s41598-020-75374-1

Sazzad HMS; McCredie L; Treloar C; Lloyd AR; Lafferty L, 2020, 'Violence and hepatitis C transmission in prison—A modified social ecological model', PLoS ONE, 15, pp. e0243106, http://dx.doi.org/10.1371/journal.pone.0243106

Mina M; Underwood A; Eltahla A; Wu BR; Walker MR; Bull RA; Lloyd AR, 2020, 'Anti-envelope antibody responses in highly exposed seronegative individuals may be associated with protection from HCV infection', Journal of Viral Hepatitis, 27, pp. 1012 - 1021, http://dx.doi.org/10.1111/jvh.13339

Dore G; Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; Mcmanus H; Butler T; Vickerman P; Martin N; Mchutchison J; Brainard D; Treloar C; Lloyd A, 2020, 'Declining HCV incidence following rapid HCV treatment scale-up in a prison network in Australia: Evidence of treatment as prevention from the SToP-C study', JOURNAL OF HEPATOLOGY, 73, pp. S127 - S127, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000786587000206&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Tran B; Vajdic CM; Webber K; Laaksonen MA; Stavrou EP; Tiller K; Suchy S; Bosco AM; Harris MF; Lloyd AR; Goldstein D, 2020, 'Self-reported health, lifestyle and social circumstances of Australian adult cancer survivors: A propensity score weighted cross-sectional study', Cancer Epidemiology, 67, http://dx.doi.org/10.1016/j.canep.2020.101773

Douglas MW; Tay ESE; Wang DS; Ong ATL; Wilson C; Phu A; Kok J; Dwyer DE; Bull RA; Lloyd AR; Applegate TL; Dore GJ; Howe AY; Harrigan R; George J, 2020, 'Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance', Hepatology Communications, 4, pp. 904 - 915, http://dx.doi.org/10.1002/hep4.1496

Sandler CX; Lloyd AR, 2020, 'Chronic fatigue syndrome: progress and possibilities', Medical Journal of Australia, 212, pp. 428 - 433, http://dx.doi.org/10.5694/mja2.50553

Bretaña NA; Gray RR; Cunningham EB; Betz-Stablein B; Ribeiro R; Graw F; Luciani F; Lloyd AR, 2020, 'Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study', Addiction, 115, pp. 901 - 913, http://dx.doi.org/10.1111/add.14830

Li H; Cameron B; Douglas D; Stapleton S; Cheguelman G; Butler T; Luciani F; Lloyd AR, 2020, 'Incident hepatitis B virus infection and immunisation uptake in Australian prison inmates', Vaccine, 38, pp. 3255 - 3260, http://dx.doi.org/10.1016/j.vaccine.2020.02.076

Brasher NA; Eltahla AA; Underwood A; Boo I; Rizzetto S; Walker MR; Rodrigo C; Luciani F; Maher L; Drummer HE; Tedla N; Lloyd AR; Bull RA, 2020, 'B cell immunodominance in primary hepatitis C virus infection', Journal of Hepatology, 72, pp. 670 - 679, http://dx.doi.org/10.1016/j.jhep.2019.11.011

Lafferty L; Rance J; Grebely J; Dore GJ; Lloyd AR; Treloar C, 2020, 'Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting', International Journal of Drug Policy, 77, http://dx.doi.org/10.1016/j.drugpo.2020.102693

Li SH; Lloyd AR; Graham BM, 2020, 'Physical and mental fatigue across the menstrual cycle in women with and without generalised anxiety disorder', Hormones and Behavior, 118, http://dx.doi.org/10.1016/j.yhbeh.2019.104667

Beilharz JE; Paterson M; Fatt S; Wilson C; Burton A; Cvejic E; Lloyd A; Vollmer-Conna U, 2020, 'The impact of childhood trauma on psychosocial functioning and physical health in a non-clinical community sample of young adults', Australian and New Zealand Journal of Psychiatry, 54, pp. 185 - 194, http://dx.doi.org/10.1177/0004867419881206

Fatt SJ; Beilharz JE; Joubert M; Wilson C; Lloyd AR; Vollmer-Conna U; Cvejic E, 2020, 'Parasympathetic activity is reduced during slow-wave sleep, but not resting wakefulness, in patients with chronic fatigue syndrome', Journal of Clinical Sleep Medicine, 16, pp. 19 - 28, http://dx.doi.org/10.5664/JCSM.8114

Fatt SJ; Beilharz JE; Joubert M; Wilson C; Lloyd AR; Vollmer-Conna U; Cvejic E, 2020, 'Parasympathetic activity is reduced during slow-wave sleep, but not resting wakefulness, in patients with chronic fatigue syndrome.', J Clin Sleep Med, 16, pp. 19 - 28, http://dx.doi.org/10.5664/jcsm.8114

Walker MR; Eltahla AA; Mina MM; Li H; Lloyd AR; Bull RA, 2020, 'Envelope-specific IgG3 and IgG1 responses are associated with clearance of acute hepatitis C virus infection', Viruses, 12, pp. 75, http://dx.doi.org/10.3390/v12010075

Geddes L; Iversen J; Wand H; Esmaeili A; Tsui J; Hellard M; Dore G; Grebely J; Dietze P; Bruneau J; Prins M; Morris MD; Shoukry NH; Lloyd AR; Kim AY; Lauer G; Cox AL; Page K; Maher L; Lloyd A; Dore G; Dietze P, 2020, 'Sex Discrepancies in the Protective Effect of Opioid Agonist Therapy on Incident Hepatitis C Infection', Clinical Infectious Diseases, 70, pp. 123 - 131, http://dx.doi.org/10.1093/cid/ciz162

Back to profile page